20.500.12556/DiRROS-19761 Sunitinib potentiates the cytotoxic effect of electrochemotherapy in pancreatic carcinoma cells One of the new treatment options for unresectable locally advanced pancreatic cancer is electro-chemotherapy (ECT), a local ablative therapy that potentiates the entry of chemotherapeutic drugs into the cells, by the application of an electric field to the tumor. Its feasibility and safety were demonstrated in preclinical and clinical studies; however, there is a lack of preclinical studies assessing the actions of different drugs used in ECT, their mechanisms and interactions with other target drugs that are used in clinical practice. Materials and methods. The aim of the study was to determine the cytotoxicity of two chemotherapeutic drugs usually used in ECT (bleomycin and cisplatin) in the BxPC-3 human pancreatic carcinoma cell line and evaluate the interactions of ECT with the targeted drug sunitinib. First, the cytotoxicity of ECT using both chemotherapeutics was determined. In the next part, the interactions of ECT and sunitinib were evaluated through determination of combined cytotoxicity, sunitinib targets and kinetics of cell death.Results. The results demonstrate that ECT is effective in pancreatic cancer cell line, especially when bleomycin is used, with the onset of cell death in the first hours after the treatment, reaching a plateau at 20 hours after the treat-ment. Furthermore, we provide the rationale for combining ECT with bleomycin and the targeted drug sunitinib to potentiate cytotoxicity. The combined treatment of sunitinib and ECT was synergistic for bleomycin only at the high-est used concentration of bleomycin 0.14 μM, whereas with lower doses of bleomycin, this effect was not observed. The interaction of ECT and treatment with sunitinib was confirmed by course of the cell death, also indicating on synergism electrochemotherapy pancreas sunitinib pancreatic cancer elektrokemoterapija trebušna slinavka sunitinib rak trebušne slinavke true false true Association of Radiology and Oncology Ljubljana Angleški jezik Slovenski jezik by Authors Neznano 2024-07-24 14:46:01 2024-07-24 14:46:01 2024-07-26 03:52:36 0000-00-00 00:00:00 2022 0 0 str. 164-172 no. 2 Vol. 56 Jun. 2022 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 2022-06-01 616-006-085 1318-2099 10.2478/raon-2022-0009 105234179 https://sciendo.com/article/10.2478/raon-2022-0009 1 ec35dec9-49a9-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27357 RAZ_Omerzel_Masa_2022.pdf RAZ_Omerzel_Masa_2022.pdf 1 95B8226E6DBEADAF47600F94FC387EB9 d1a330f5b0006de32ef615cda6658a87ebbf1165ad2082b506e71ee006c2479f 19f6c1e8-49aa-11ef-b487-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=27358 Onkološki inštitut Ljubljana 0 0 0